ENANTA PHARMACEUTICALS, INC Other Revenue, Net (Deprecated 2018-01-31)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Other Revenue, Net (Deprecated 2018-01-31) of $576.00 thousand for the 12-month period ending 2016-09-30, per its 10-K filed 2016-12-09.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2017-08-09
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $576.00K, a 47.92% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $576.00K, a 68.05% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $1.80M, a 76.71% decline from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $7.74M, a 27.89% increase from fiscal 2013.
- ENANTA PHARMACEUTICALS, INC other revenue, net (deprecated 2018-01-31) for fiscal 2013 was $6.05M.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $0.00 derived: sum of 2 quarters · filed 2017-08-09 | $0.00 derived: sum of 3 quarters · filed 2017-08-09 | $576.00K 10-K · filed 2016-12-09 |
| 2016-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | $0.00 derived: sum of 2 quarters · filed 2017-08-09 | $576.00K 10-Q · filed 2017-08-09 | $658.00K derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $576.00K 10-Q · filed 2017-05-10 | $658.00K derived: sum of 3 quarters · filed 2017-05-10 | $867.00K derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $576.00K 10-Q · filed 2017-02-09 | $658.00K derived: sum of 2 quarters · filed 2017-02-09 | $867.00K derived: sum of 3 quarters · filed 2017-02-09 | $1.27M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-09-30 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $291.00K derived: sum of 2 quarters · filed 2016-12-09 | $697.00K derived: sum of 3 quarters · filed 2016-12-09 | $1.80M 10-K · filed 2016-12-09 |
| 2015-06-30 | $209.00K 10-Q · filed 2016-08-09 | $615.00K derived: sum of 2 quarters · filed 2016-08-09 | $1.72M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $406.00K 10-Q · filed 2016-05-10 | $1.51M 10-Q · filed 2016-05-10 | ||
| 2014-12-31 | $1.11M 10-Q · filed 2016-02-09 | |||
| 2014-09-30 | $7.74M 10-K · filed 2016-12-09 | |||
| 2013-09-30 | $6.05M 10-K · filed 2015-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |